ABBV · News · 20260822N
Revenue Performance and Mix
AbbVie Inc. · 2026-08-22 · Importance 37 · Surprise 6
AbbVie reported second-quarter 2026 revenue of $16.99 billion and earnings of $3.65 per share. Second-quarter growth was led particularly by the immunology medicines SKYRIZI and RINVOQ. The reported results exceeded expectations, according to third-party coverage.
Key facts
- Q2 2026 revenue growth was driven particularly by the immunology drugs Skyrizi and Rinvoq. source